Abstract:Objective: Impulse control behaviors (ICBs) frequently coexist with Parkinson's disease (PD). However, the predictors of ICBs in PD remain unclear, and there is limited data on the biological correlates of ICBs in PD. In this study, we examined clinical, imaging, and biological variables to identify factors associated with longitudinal changes in ICBs in early-stage PD. Methods: The data for this study were obtained from the Parkinson's Progression Markers Initiative, an international prospective cohort study that evaluates markers of disease progression in PD. We examined clinical, imaging, and biological variables to determine their associations with ICBs over a period of up to 5 years. Cox regression models were employed to investigate the predictors of ICBs in early-stage, untreated PD. Results: The study enrolled 401 individuals with PD and 185 healthy controls (HC). At baseline, 83 PD subjects (20.7%) and 36 HC (19.5%) exhibited ICBs. Over the course of 5 years, the prevalence of ICBs increased in PD (from 20.7% to 27.3%, p < 0.001), while it decreased in HC (from 19.5% to 15.2%, p < 0.001). Longitudinally, the presence of ICBs in PD was associated with depression, anxiety, autonomic dysfunction, and excessive daytime sleepiness (EDS). However, there was no significant association observed with cognitive dysfunction or motor severity. Treatment with dopamine agonists was linked to ICBs at years 3 and 4. Conversely, there was no association found between ICBs and presynaptic dopaminergic dysfunction. Additionally, biofluid markers in baseline and the first year did not show a significant association with ICBs. A predictive index for ICBs was generated, incorporating three baseline characteristics: anxiety, rapid eye movement sleep behavior disorder (RBD), and p-tau levels in cerebrospinal fluid (CSF). Conclusion: During the early stages of PD, there is a notable increase in ICBs over time. These ICBs are associated with depression, anxiety, autonomic dysfunction, EDS, and the use of dopaminergic medications, particularly dopamine agonists. Anxiety, RBD, and p-tau levels in CSF are identified as predictors for the incident development of ICBs in early PD. Further longitudinal analyses will provide a more comprehensive understanding of the associations between ICBs and imaging findings, as well as biomarkers. These analyses will help to better characterize the relationships and implications of these factors in the context of ICBs in early PD.

Predictors for early‐onset psychotic symptoms in patients newly diagnosed with Parkinson's disease without psychosis at baseline: A 5‐year cohort study

Association of Concurrent Olfactory Dysfunction and Probable Rapid Eye Movement Sleep Behavior Disorder with Early Parkinson's Disease Progression

Different Patterns of Exosomal Α‐synuclein Between Parkinson's Disease and Probable Rapid Eye Movement Sleep Behavior Disorder

Predictors of the Rapid Progression in Prodromal Parkinson’s Disease: A Longitudinal Follow-Up Study

Predictors of Cognitive Impairment in Newly Diagnosed Parkinson's Disease with Normal Cognition at Baseline: A 5-Year Cohort Study.

Multi-predictor modeling for predicting early Parkinson's disease and non-motor symptoms progression

Characterizing Mild Cognitive Impairment in Prodromal Parkinson’s Disease: A Community‐based Study in China

Assessing impulse control behaviors in early Parkinson's disease: a longitudinal study

Two Distinct Trajectories of Clinical and Neurodegeneration Events in Parkinson’s Disease

Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons

Parkinson's disease psychosis associated with accelerated multidomain cognitive decline

Wider and Faster Degeneration of White Matter in Parkinson’s Disease with Possible REM Sleep Behaviour Disorder

Constructing Prediction Models for Excessive Daytime Sleepiness by Nomogram and Machine Learning: A Large Chinese Multicenter Cohort Study

0894 Impulsivity across early stages of synucleinopathy: from high-risk relatives, REM sleep behavior disorder to Parkinson’s disease

Predictors of cognitive impairment in Parkinson’s disease: a systematic review and meta-analysis of prospective cohort studies

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease

Prediction of Parkinson's disease subsequent to severe depression: a ten-year follow-up study

Parkinson’s disease psychosis associated with accelerated multi-domain cognitive decline

Non-motor Features of Parkinson’s Disease in a Nested Case–control Study of US Men

Associations between Sleep Disorders and Impulsive-Compulsive Behaviors in Parkinson's Disease: A Prospective Cohort Study